Literature DB >> 10629401

Extended prophylaxis against venous thromboembolism following total hip and knee replacement.

R D Hull1, G F Pineo.   

Abstract

The recently reported reductions in the incidence of post-operative venous thromboembolism (VTE) are related to the widespread use of prophylactic anticoagulants. Many uncertainties remain with regard to the most effective ways to use thromboprophylaxis, however. The trend towards shorter hospital stays means that patients may receive less than the recommended 7-10 days of prophylaxis. Prolonged periods of thromboprophylaxis may be beneficial for patients at high risk of post-operative VTE, such as those undergoing major orthopaedic surgery. The relative rarity of symptomatic deep vein thrombosis and pulmonary embolism means that very large patient populations are required for studies that rely on clinical endpoints, but studies using venographic endpoints have shown 28-35 days of prophylaxis with low-molecular-weight heparin to be more effective than 10-14 days. Other factors that may influence the efficacy of thromboprophylaxis include the timing of the first injection and the choice of agent. Copyright 1999 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629401     DOI: 10.1159/000054109

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  9 in total

Review 1.  [An update on thrombosis prophylaxis in orthopaedic and accident surgery].

Authors:  J Grifka; S Haas; L Hovy; W Knopp; H L Refior; M Schürmann; T Wirth
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

2.  [Prevention of deep vein thrombosis in surgical departments].

Authors:  S Haas
Journal:  Chirurg       Date:  2004-03       Impact factor: 0.955

3.  The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies.

Authors:  Michael H Huo; Alex C Spyropoulos
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

4.  Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

Authors:  Russell D Hull; Sebastian M Schellong; Victor F Tapson; Manuel Monreal; Meyer-Michel Samama; Alexander G G Turpie; Peter Wildgoose; Roger D Yusen
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

5.  [Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients].

Authors:  K Fecher; W Ewald; A Fürst; V Hohmann; P Bramlage
Journal:  Unfallchirurg       Date:  2013-03       Impact factor: 1.000

Review 6.  [Preventing venous thromboembolism].

Authors:  A Encke; S Haas
Journal:  Chirurg       Date:  2007-02       Impact factor: 0.955

Review 7.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 8.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

Authors:  Alexander Thomas Cohen; Theodore Erich Spiro; Harry Roger Büller; Lloyd Haskell; Dayi Hu; Russell Hull; Alexandre Mebazaa; Geno Merli; Sebastian Schellong; Alex Spyropoulos; Victor Tapson
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.